• Users Online: 89
  • Print this page
  • Email this page
CASE REPORT
Year : 2020  |  Volume : 7  |  Issue : 2  |  Page : 78-81

A case of small-cell lung cancer harboring an epidermal growth factor receptor mutation that responded to epidermal growth factor receptor tyrosine kinase inhibitor treatment


1 Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou and Chang Gung University College of Medicine, Taoyuan, Taiwan
2 Department of Anatomic Pathology, Chang Gung Memorial Hospital at Linkou and Chang Gung University College of Medicine, Taoyuan, Taiwan

Correspondence Address:
Dr. Cheng- Lung Hsu
Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou and Chang Gung University College of Medicine, No. 5, Fu-Hsing Street, Kwei-Shan, Taoyuan
Taiwan
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/JCRP.JCRP_31_19

Rights and Permissions

Epidermal growth factor receptor (EGFR) mutations are extremely rare in small-cell lung cancer (SCLC), and the efficacy of EGFR tyrosine kinase inhibitors (TKIs) in SCLC is unclear. Herein, we present a case with SCLC harboring an EGFR mutation who also responded to a second-generation EGFR TKI (afatinib).


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed817    
    Printed62    
    Emailed0    
    PDF Downloaded121    
    Comments [Add]    

Recommend this journal